Interested in kidney cancer? Our colleagues in the Early Cancer Institute are offering two funded, non-clinical PhD projects in kidney cancer: www.cam.ac.uk/jobs/early-c...

The UK’s first one-stop kidney cancer clinic at @cuh.nhs.uk is transforming kidney cancer diagnosis. With a confocal microscope, patients can get a biopsy, diagnosis & treatment plan – all on the same day. Find out more: crukcambridgecentre.org.uk/news/one-sto... @crukcamurol.bsky.social

🚨 We’re looking for an Academic Clinical Fellow in Urology ST1/2 level. An exciting opportunity to join the University of Cambridge, contribute to cutting-edge research + develop your clinical career. 📍Cambridge 🗓️ Applications open now via Oriel: 👉 lnkd.in/eUJgPwC9

The third blog in our series on INKCC is out now: recommendations for assessing pathological response in neoadjuvant kidney cancer trials Read more 👇 www.cambridge-urologicalmalignancies.org.uk/post/towards...

Towards a standard for evaluating pathological response in neoadjuvant kidney cancer trials

This third blog in our series on International Neoadjuvant Kidney Cancer Consortium (INKCC), outlines the first guidelines published by the consortium. One area in which the INKCC Delphi process could...

cambridge-urologicalmalignancies.org.uk

CRUK Cambridge Centre: Urological Malignancies@crukcamurol.bsky.social · last yr.

We've just shared the second blog in our series about the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC), a group of experts building strategy in research on neoadjuvant therapies for patients with kidney cancer: www.cambridge-urologicalmalignancies.org.uk/post/finding...

🚨 New blog: Our researchers publish new data demonstrating the prevalence of kidney cancer in high-risk individuals, using data from our @yorkshirecancer.bsky.social funded kidney screening trial. Read more 👉 www.cambridge-urologicalmalignancies.org.uk/post/urologi...

We've just shared the second blog in our series about the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC), a group of experts building strategy in research on neoadjuvant therapies for patients with kidney cancer: www.cambridge-urologicalmalignancies.org.uk/post/finding...

Finding and building consensus in kidney cancer trials

In this second part of our blog series on the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC) we consider how the group has found and built consensus, and how to proceed through...

cambridge-urologicalmalignancies.org.uk

Congratulations to Harveer and Simon on publishing outcomes from their CANCAP03 trial

Cancer Research UK Cambridge Centre@crukcamcentre.bsky.social · last yr.

A short course of targeted therapy prior to surgery can influence the biology of prostate cancer, even in men without known DNA repair gene mutations, finds a trial led by @crukcamurol.bsky.social members. Read more ➡️ crukcambridgecentre.org.uk/news/cambrid... @cambridgebrc.bsky.social @cuh.nhs.uk

Congratulations our own Tom Mitchell on winning the Christopher G Wood Rising Star Award at #IKCSEU2025 earlier this month - very well deserved!

New analysis by Sheffield Centre for Health and Related Research in collaboration with UMVI researchers, using data from our world-first Yorkshire Kidney Screening Trial, shows that screening for kidney cancer is potentially cost effective. Read more: doi.org/10.1038/s414... (1/6)

Rebecca Wray, joint first author on this paper, presented her work at the @theaacr.bsky.social Annual Meeting this weekend

CRUK Cambridge Centre: Urological Malignancies@crukcamurol.bsky.social · 2y ago

New work led by James Jones, published this week in @natcomms.nature.com, has discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus (VTT) using a drug called axitinib. crukcambridgecentre.org.uk/news/researc...

Using a machine learning model to analyse data from the NAXIVA trial, @crukcamurol.bsky.social members have discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus using a drug called axitinib. Read more: crukcambridgecentre.org.uk/news/researc...

New work led by James Jones, published this week in @natcomms.nature.com, has discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus (VTT) using a drug called axitinib. crukcambridgecentre.org.uk/news/researc...